SurePath沉降式液基细胞采集技术应用于甲状腺细针穿刺细胞学诊断的准确性评价
作者:
作者单位:

1.南京医科大学第一附属医院内分泌科,江苏 南京 210029 ; 2.南京大学医学院附属鼓楼医院内分泌科,江苏 南京 210008 ; 3.南京医科大学第一附属医院病理科,江苏 南京 210029

作者简介:

通讯作者:

中图分类号:

基金项目:

江苏省卫生健康委员会重点医学科研项目(ZDB2020035);江苏省自然科学基金(BK20220715);伊犁州临床医学研究院研究基金(yl2021ms03)


Evaluation of the accuracy of SurePath liquid ⁃ based cytology in thyroid fine ⁃ needle aspiration
Author:
Affiliation:

1.Department of Endocrinology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029 ; 2.Department of Endocrinology,Drum Tower Hospital affiliated to Nanjing University Medical School,Nanjing 210008 ; 3.Department of Pathology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029 ,China

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:评价SurePath沉降式液基细胞采集(SurePath-liquid based cytology,SurePath-LBC)技术应用于甲状腺细针穿刺细胞学病理诊断的准确性。方法:回顾性收集南京医科大学第一附属医院甲乳外科行手术治疗且有完整术前细胞病理和术后病理资料的患者共计352例(363个甲状腺结节)。术前均采用SurePath-LBC技术进行细胞学制片,并对比细胞病理诊断与手术病理。对其中264例同时进行了BRAFV600E 突变检测。结果:细胞病理提示可疑恶性共计112例,110例可疑乳头状癌(pap- illary thyroid carcinoma,PTC),2例可疑髓样癌(medullary thyroid carcinoma,MTC)。110例可疑PTC最终手术病理确定为PTC 106例,不典型滤泡性腺瘤1例,滤泡状癌(follicular thyroid carcinoma,FTC)1例,恶性潜能未定的甲状腺高分化肿瘤2例,诊断一致率为96.4%;2例可疑MTC的病例最终手术病理均证实为MTC,一致率为100.0%。总体可疑恶性病例与手术病理吻合率为97.3%。细胞病理提示恶性的甲状腺结节共计211例(210例PTC,1例MTC),210例PTC中,手术病理证实为PTC 209例, 另 1 例提示乳头状增生伴不典型增生,诊断一致率为99.5%;细胞学诊断为MTC的病例,手术病理也确定为MTC,一致率为 100.0%。总体恶性病例与手术病理吻合率为99.5%。BRAFV600E 在可疑恶性和恶性中的突变率分别为82.3%和95.5%。细胞学诊断为良性的结节共计7例,最终手术病理3例为结节性甲状腺肿,2例滤泡性肿瘤,2例PTC。不典型病变的结节共23例,其中TI-RADS 4B 及以上19例,BRAFV600E 突变率为62.5%(10/16),总体恶性率87.0%。无诊断的病例10例,BRAFV600E 突变率为 57.1%(4/7),总体恶性率为50.0%。结论:采用SurePath-LBC方法进行甲状腺细针穿刺标本制片,细胞病理学诊断为可疑恶性或恶性时与最终手术病理诊断有高度一致性,对于具体的恶性类别也有准确的提示作用,该技术对于甲状腺结节术前诊断具有非常重要的参考价值,值得进一步推广和应用。

    Abstract:

    Objective:To evaluate the accuracy of the SurePath - liquid based cytology(SurePath - LBC)technique in the cytopathological dignosis of fine needle aspiration(FNA)for thyroid nodules. Methods:A retrospective study was conducted on 352 patients(363 thyroid nodules)from the Thyroid and Breast Surgery Department of the First Affiliated Hospital of Nanjing Medical University,who underwent thyroidectomy and had complete preoperative cytopathological and postoperative pathological data. The SurePath -LBC was used for cytological diagnosis before surgery,and the cytopathological diagnoses were compared with the surgical pathology results. 363 independent cytology reports were obtained from these patients. BRAFV600E mutation testing was also performed on 264 cases. Results:Cytopathology suggested suspicious for malignancy(SM)in a total of 112 cases,including 110 cases of suspected papillary thyroid carcinoma(PTC)and 2 cases of suspected medullary thyroid carcinoma(MTC). Among the 110 suspected PTC cases,surgical pathology confirmed 106 cases as PTC,1 case as atypical adenoma,1 case as follicular thyroid carcinoma(FTC), and 2 cases as well differentiated tumors of uncertain malignant potential(WT-UMP),with a diagnosis accuracy of 96.4%. Both cases suspicious for MTC were confirmed as MTC by surgical pathology,with an accuracy of 100.0%. The overall accuracy for SM cases with surgical pathology was 97.3%. 211 nodules were reported as“malignant,M”(210 PTC and 1 case MTC). Among 210 PTC cases,209 cases were confirmed by histology,and 1 case was confirmed to be atypical adenoma,yielding a diagnosis accuracy of 99.5%. The case diagnosed as MTC by cytology was also confirmed as MTC by surgical pathology,with a diagnosis accuracy of 100.0%. The overall diagnosis accuracy for suspected M cases with surgical pathology was 99.5%. The BRAFV600E mutation rates of SM and M cases were 82.3% and 95.5%,respectively. Among the seven nodules cytologically diagnosed as benign,final surgical pathology revealed 3 cases of nodular goiter,2 cases of follicular tumors,and 2 cases of PTC. There were 23 thyroid nodules reported as atypia of undetermined significance(AUS),19 cases of which were classified ase TI-RADS 4B or higer,with a BRAFV600E mutation rate of 62.5%(10/16)and an overall malignancy rate of 87.0%. In the 10 cases with nondiagnostic(ND)results,the BRAFV600E mutation rate was 57.1%(4/7), with an overall malignancy rate of 50.0%. Conclusion:The SurePath -LBC method for preparing cytological specimens from thyroid FNA for the diagnosis of SM or M showed high concordance with surgical pathological diagnosis. It is also accurately indicated specific malignancy types. This technique has significant reference value for the preoperative diagnosis of thyroid nodules and is worth further promotion and application.

    参考文献
    相似文献
    引证文献
引用本文

谷志远,蔡赟,陈欢欢,方海生,戎荣,杨涛,王晓东,刘晓云. SurePath沉降式液基细胞采集技术应用于甲状腺细针穿刺细胞学诊断的准确性评价[J].南京医科大学学报(自然科学版),2024,(11):1550-1557,1580

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2024-03-23
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-11-15
  • 出版日期:
关闭